Kenny, apart from the 'Technical Aspect' that you mention (which...

Kenny, apart from the 'Technical Aspect' that you mention (which I believe should play out)
we know that patient recruitment has increased every quarter from the original 5 patients
announced in March 2022, therefore, completion of the current trial is highly likely to occur
before the end of 2022.

Also of major significance is that the Interim results show no safety or tolerability issues,
and testing has also shown the ability of the imaging agent to reach the lymph nodes.
All this helps to color in the big picture in a 'Fundamental Aspect'. Sure, the inordinate
amount of time taken to achieve a satisfactory trial cohort has weighed heavily on the SP
and that's why (I believe) the SP is where it is.

For me, IBX still remains an intriguing investment for a portion of a portfolio with an appetite
for risk and LT.